Filing Details
- Accession Number:
- 0000950170-25-002486
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-06 20:15:41
- Reporting Period:
- 2025-01-03
- Accepted Time:
- 2025-01-06 20:15:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1607678 | Viking Therapeutics Inc. | VKTX | Pharmaceutical Preparations (2834) | 461073877 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1838112 | Marianna Mancini | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2025-01-03 | 44,533 | $0.00 | 406,682 | No | 4 | A | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2025-01-03 | 21,667 | $0.00 | 428,349 | No | 4 | A | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2025-01-06 | 49,115 | $42.69 | 379,234 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2025-01-06 | 5,100 | $43.32 | 374,134 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2025-01-03 | 37,200 | $0.00 | 37,200 | $42.89 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 37,200 | 2026-01-03 | 2035-01-03 | No | 4 | A | Direct |
Footnotes
- Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
- The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal.
- These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.20 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 to $43.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 25% of the shares subject to the option will vest on each anniversary of the grant date.
Billionaire Hedge Funds
